Targeting RAS–ERK signalling in cancer: promises and challenges (original) (raw)

• Montagut, C. & Settleman, J. Targeting the RAF–MEK–ERK pathway in cancer therapy. Cancer Lett. 283, 125–134 (2009).
  Article CAS PubMed Google Scholar
• Roberts, P. J. & Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291–3310 (2007).
  Article CAS PubMed Google Scholar
• Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279–3290 (2007).
  Article CAS PubMed Google Scholar
• Matallanas, D. et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer 2, 232–260 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
  Article CAS PubMed Google Scholar
• Cantwell-Dorris, E. R., O'Leary, J. J. & Sheils, O. M. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol. Cancer Ther. 10, 385–394 (2011).
  Article CAS PubMed Google Scholar
• Baines, A. T., Xu, D. & Der, C. J. Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem. 3, 1787–1808 (2011).
  Article CAS PubMed Google Scholar
• Castellano, E. & Downward, J. RAS Interaction with PI3K: more than just another effector pathway. Genes Cancer 2, 261–274 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Downward, J. Targeting RAS and PI3K in lung cancer. Nature Med. 14, 1315–1316 (2008).
  Article CAS PubMed Google Scholar
• Neel, N. F. et al. The RalGEF-Ral effector signaling network: the road less traveled for anti-ras drug discovery. Genes Cancer 2, 275–287 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Young, A. et al. Ras signaling and therapies. Adv. Cancer Res. 102, 1–17 (2009).
  Article CAS PubMed Google Scholar
• James, G., Goldstein, J. L. & Brown, M. S. Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc. Natl Acad. Sci. USA 93, 4454–4458 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Whyte, D. B. et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272, 14459–14464 (1997).
  Article CAS PubMed Google Scholar
• Zimmermann, G. et al. Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling. Nature 497, 638–642 (2013).
  Article CAS PubMed Google Scholar
• Maurer, T. et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl Acad. Sci. USA 109, 5299–5304 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Sun, Q. et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. 51, 6140–6143 (2012).
  Article CAS Google Scholar
• Burns, M. C. et al. Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proc. Natl Acad. Sci. USA 111, 3401–3406 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Shima, F. et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc. Natl Acad. Sci. USA 110, 8182–8187 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Wellbrock, C., Karasarides, M. & Marais, R. The RAF proteins take centre stage. Nature Rev. Mol. Cell Biol. 5, 875–885 (2004).
  Article CAS Google Scholar
• Weber, C. K., Slupsky, J. R., Kalmes, H. A. & Rapp, U. R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61, 3595–3598 (2001).
  CAS PubMed Google Scholar
• Cutler, R. E. Jr., Stephens, R. M., Saracino, M. R. & Morrison, D. K. Autoregulation of the Raf-1 serine/threonine kinase. Proc. Natl Acad. Sci. USA 95, 9214–9219 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Rev. Drug Discov. 5, 835–844 (2006).
  Article CAS Google Scholar
• Emuss, V., Garnett, M., Mason, C. & Marais, R. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res. 65, 9719–9726 (2005).
  Article CAS PubMed Google Scholar
• Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855–867 (2004).
  Article CAS PubMed Google Scholar
• Pritchard, C. A., Samuels, M. L., Bosch, E. & McMahon, M. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol. Cell. Biol. 15, 6430–6442 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Imielinski, M. et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J. Clin. Invest. 124, 1582–1586 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Nelson, D. S. et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood 123, 3152–3155 (2014).
  Article CAS PubMed Google Scholar
• Chen, J., Fujii, K., Zhang, L., Roberts, T. & Fu, H. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc. Natl Acad. Sci. USA 98, 7783–7788 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• O'Neill, E., Rushworth, L., Baccarini, M. & Kolch, W. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306, 2267–2270 (2004).
  Article CAS PubMed Google Scholar
• Wang, S., Ghosh, R. N. & Chellappan, S. P. Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation. Mol. Cell. Biol. 18, 7487–7498 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Ehrenreiter, K. et al. Raf-1 regulates Rho signaling and cell migration. J. Cell Biol. 168, 955–964 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Badalian-Very, G. et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116, 1919–1923 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Haroche, J. et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120, 2700–2703 (2012).
  Article CAS PubMed Google Scholar
• Eisen, T. et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer 95, 581–586 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in _BRAF_-mutant melanoma. Nature 467, 596–599 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041–3046 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Falchook, G. S. et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a Phase 1 dose-escalation trial. Lancet 379, 1893–1901 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Hauschild, A. et al. Dabrafenib in _BRAF_-mutated metastatic melanoma: a multicentre, open-label, Phase 3 randomised controlled trial. Lancet 380, 358–365 (2012).
  Article CAS PubMed Google Scholar
• Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209–221 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427–430 (2010).
  CAS PubMed PubMed Central Google Scholar
• Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431–435 (2010).
  Article CAS PubMed Google Scholar
• Joseph, E. W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl Acad. Sci. USA 107, 14903–14908 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Halaban, R. et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell. Melanoma Res. 23, 190–200 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Karreth, F. A., DeNicola, G. M., Winter, S. P. & Tuveson, D. A. C-Raf inhibits MAPK activation and transformation by B-RafV600E. Mol. Cell 36, 477–486 (2009).
  Article CAS PubMed Google Scholar
• Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl. J. Med. 364, 2507–2516 (2011).
  Article CAS PubMed Google Scholar
• Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. New Engl. J. Med. 363, 809–819 (2010).
  Article CAS PubMed Google Scholar
• Shi, H. et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80–93 (2014).
  Article CAS PubMed Google Scholar
• Haroche, J. et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121, 1495–1500 (2013).
  Article CAS PubMed Google Scholar
• Holderfield, M. et al. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell 23, 594–602 (2013).
  Article CAS PubMed Google Scholar
• Roring, M. et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J. 31, 2629–2647 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Wu, X. et al. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants. Mol. Cell. Biol. 32, 3872–3890 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Hu, J. et al. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 154, 1036–1046 (2013).
  Article CAS PubMed Google Scholar
• Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F. & Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542–545 (2009).
  Article CAS PubMed Google Scholar
• Lavoie, H. et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nature Chem. Biol. 9, 428–436 (2013).
  Article CAS Google Scholar
• Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387–390 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Freeman, A. K., Ritt, D. A. & Morrison, D. K. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol. Cell 49, 751–758 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. New Engl. J. Med. 366, 207–215 (2012).
  Article CAS PubMed Google Scholar
• Callahan, M. K. et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. New Engl. J. Med. 367, 2316–2321 (2012).
  Article CAS PubMed Google Scholar
• Abdel-Wahab, O. et al. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF and NRAS mutant malignancies. Cancer Discov. 4, 538–545 (2014).
  Article PubMed PubMed Central Google Scholar
• Carlino, M. S. et al. New _RAS_-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2013.51.5783 (2014).
• Poulikakos, P. I. & Rosen, N. Mutant BRAF melanomas—dependence and resistance. Cancer Cell 19, 11–15 (2011).
  Article CAS PubMed Google Scholar
• Stuart, D. D. et al. Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor. Cancer Res. 72, S1 (2012).
  Google Scholar
• Nakamura, A. et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 73, 7043–7055 (2013).
  Article CAS PubMed Google Scholar
• Basile, K. J., Le, K., Hartsough, E. J. & Aplin, A. E. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell. Melanoma Res. 27, 479–484 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Sievert, A. J. et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc. Natl Acad. Sci. USA 110, 5957–5962 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Roskoski, R. Jr MEK1/2 dual-specificity protein kinases: structure and regulation. Biochem. Biophys. Res. Commun. 417, 5–10 (2012).
  Article CAS PubMed Google Scholar
• Sebolt-Leopold, J. S. MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors. Curr. Pharm. Design 10, 1907–1914 (2004).
  Article CAS Google Scholar
• Marks, J. L. et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 68, 5524–5528 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Murugan, A. K., Dong, J., Xie, J. & Xing, M. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle 8, 2122–2124 (2009).
  Article CAS PubMed Google Scholar
• Haura, E. B. et al. A Phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin. Cancer Res. 16, 2450–2457 (2010).
  Article CAS PubMed Google Scholar
• Rinehart, J. et al. Multicenter Phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22, 4456–4462 (2004).
  Article CAS PubMed Google Scholar
• Banerji, U. et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a Phase I open-label multicenter trial in patients with advanced cancer. Clin. Cancer Res. 16, 1613–1623 (2010).
  Article CAS PubMed Google Scholar
• Lorusso, P. M. et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 23, 5281–5293 (2005).
  Article CAS PubMed Google Scholar
• Brown, A. P., Carlson, T. C., Loi, C. M. & Graziano, M. J. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, D0325901, in the rat following oral and intravenous administration. Cancer Chemother. Pharmacol. 59, 671–679 (2007).
  Article CAS PubMed Google Scholar
• Sebolt-Leopold, J. S. et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 5, 810–816 (1999).
  Article CAS PubMed Google Scholar
• Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006).
  Article CAS PubMed Google Scholar
• LoRusso, P. M. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin. Cancer Res. 16, 1924–1937 (2010).
  Article CAS PubMed Google Scholar
• Yeh, T. C. et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13, 1576–1583 (2007).
  Article CAS PubMed Google Scholar
• Davies, B. R. et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol. Cancer Ther. 6, 2209–2219 (2007).
  Article CAS PubMed Google Scholar
• Adjei, A. A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139–2146 (2008).
  Article CAS PubMed Google Scholar
• Leijen, S. et al. A Phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 68, 1619–1628 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kirkwood, J. M. et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 18, 555–567 (2012).
  Article CAS PubMed Google Scholar
• Janne, P. A. et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, Phase 2 study. Lancet Oncol. 14, 38–47 (2013).
  Article PubMed CAS Google Scholar
• Gilmartin, A. G. et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17, 989–1000 (2011).
  Article CAS PubMed Google Scholar
• Infante, J. R. et al. A Phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. Eur. J. Cancer 49, 2077–2085 (2013).
  Article CAS PubMed Google Scholar
• Falchook, G. S. et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a Phase 1 dose-escalation trial. Lancet Oncol. 13, 782–789 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. New Engl. J. Med. 367, 107–114 (2012).
  Article CAS PubMed Google Scholar
• Carlino, M. S. et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol. Oncol. 8, 544–554 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New Engl. J. Med. 367, 1694–1703 (2012).
  Article CAS PubMed Google Scholar
• Kim, K. et al. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br. J. Haematol. 149, 537–549 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Choo, E. F. et al. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions. Drug Metabolism Dispos. 40, 919–927 (2012).
  Article CAS Google Scholar
• Iverson, C. et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res. 69, 6839–6847 (2009).
  Article CAS PubMed Google Scholar
• Hatzivassiliou, G. et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 501, 232–236 (2013).
  Article CAS PubMed Google Scholar
• Dong, Q. et al. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. Bioorg. Med. Chem. Lett. 21, 1315–1319 (2011).
  Article CAS PubMed Google Scholar
• Martinez-Garcia, M. et al. First-in-human, Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin. Cancer Res. 18, 4806–4819 (2012).
  Article CAS PubMed Google Scholar
• Leijen, S. et al. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin. Cancer Res. 18, 4794–4805 (2012).
  Article CAS PubMed Google Scholar
• Ascierto, P. A. et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label Phase 2 study. Lancet Oncol. 14, 249–256 (2013).
  Article CAS PubMed Google Scholar
• Kim, K. B. et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic _BRAF_-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. 31, 482–489 (2013).
  Article CAS PubMed Google Scholar
• Dougherty, M. K. et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 17, 215–224 (2005).
  Article CAS PubMed Google Scholar
• Ritt, D. A., Monson, D. M., Specht, S. I. & Morrison, D. K. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol. Cell. Biol. 30, 806–819 (2010).
  Article CAS PubMed Google Scholar
• Fritsche-Guenther, R. et al. Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol. Systems Biol. 7, 489 (2011).
  Article CAS Google Scholar
• Young, A., Lou, D. & McCormick, F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 3, 112–123 (2013).
  Article CAS PubMed Google Scholar
• Ishii, N. et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res. 73, 4050–4060 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Lito, P. et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 25, 697–710 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Boulton, T. G. et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65, 663–675 (1991).
  Article CAS PubMed Google Scholar
• Haystead, T. A., Dent, P., Wu, J., Haystead, C. M. & Sturgill, T. W. Ordered phosphorylation of p42mapk by MAP kinase kinase. FEBS Lett. 306, 17–22 (1992).
  Article CAS PubMed Google Scholar
• Aronov, A. M. et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J. Med. Chem. 52, 6362–6368 (2009).
  Article CAS PubMed Google Scholar
• Hatzivassiliou, G. et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol. Cancer Ther. 11, 1143–1154 (2012).
  Article CAS PubMed Google Scholar
• Ohori, M. et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem. Biophys. Res. Commun. 336, 357–363 (2005).
  Article CAS PubMed Google Scholar
• Morris, E. J. et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 3, 742–750 (2013).
  Article CAS PubMed Google Scholar
• Sullivan, R. J. & Flaherty, K. T. Resistance to BRAF-targeted therapy in melanoma. Eur. J. Cancer 49, 1297–1304 (2013).
  Article CAS PubMed Google Scholar
• Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227–235 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100–103 (2012).
  Article CAS PubMed Google Scholar
• Montero-Conde, C. et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 3, 520–533 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505–509 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500–504 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Lito, P. et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668–682 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Sun, C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118–122 (2014).
  Article CAS PubMed Google Scholar
• Whittaker, S. R. et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 3, 350–362 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Maertens, O. et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 3, 338–349 (2013).
  Article CAS PubMed Google Scholar
• Nissan, M. H. et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 74, 2340–2350 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Lin, L. et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc. Natl Acad. Sci. USA 111, E748–E757 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973–977 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Shi, H. et al. Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Commun. 3, 724 (2012).
  Article CAS Google Scholar
• Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683–695 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Girotti, M. R. et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 3, 158–167 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Montagut, C. et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853–4861 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968–972 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Marusiak, A. A. et al. Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Nature Commun. 5, 3901 (2014).
  Article CAS Google Scholar
• Emery, C. M. et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc. Natl Acad. Sci. USA 106, 20411–20416 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Wagle, N. et al. MAP kinase pathway alterations in _BRAF_-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 4, 61–68 (2014).
  Article CAS PubMed Google Scholar
• Kopetz, S. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Onc. Abstr. 28, 3534 (2010).
  Article Google Scholar
• Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251–255 (2013).
  Article CAS PubMed Google Scholar
• Carlino, M. S. et al. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol. Cancer Ther. 12, 1332–1342 (2013).
  Article CAS PubMed Google Scholar
• Deng, Y. et al. Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase. J.Med.Chem http://dx.doi.org/10.1021/jm500847m (2014).
• Chaikuad, A. et al. A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Nature Chem. Biol. 10, 853–860 (2014).
  Article CAS Google Scholar